Show notes
Big Pharma dealmaking has picked up, but the biotech path to a signed agreement is still anything but simple. In this episode, recorded at Fierce Biotech Week, Senior Editor James Waldron leads a discussion on the evolving BD&L landscape across pharma and biotech.
Transcript
Transcript not available for this episode yet.
More from The Top Line
GSK’s first lung cancer approval, a new IPO path and more
Jul 24, 202611 min
Why modern clinical trials need a finance-first strategy (Sponsored)
Jul 20, 202617 min
5 emerging biotech hubs
Jul 17, 202624 min
Decision readiness is the next AI advantage (Sponsored)
Jul 13, 202618 min
A $10B deal, China trial scrutiny and highlights from ADA 2026
Jul 10, 202624 min